Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment

Transfusion

Volumn 54, Issue 7, 2014, Pages 1798-1807

  Winter, Kelly M ^a   Johnson, Lacey ^a   Kwok, Matthew ^a   Vidovic, Diana ^a   Hyland, Ryan A ^a   Mufti, Nina ^b   Erickson, Anna ^b   Marks, Denese C ^a  

^a Research and Development   (Australia)

^b CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; AMUSTALINE; GLYCOPHORIN A; HEMOGLOBIN; LACTIC ACID;

ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE FUNCTION AND CHARACTERISTICS; ERYTHROCYTE STRUCTURE; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE VOLUME; FLOW CYTOMETRY; GLUCOSE INTAKE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; METABOLISM; PH; POTASSIUM TRANSPORT; PRACTICE GUIDELINE; ROOM TEMPERATURE; STORAGE TEMPERATURE; VASCULARIZATION;

2,3-DIPHOSPHOGLYCERATE; ACRIDINES; ADENOSINE TRIPHOSPHATE; ALKYLATING AGENTS; BLOOD PRESERVATION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; ERYTHROCYTE COUNT; ERYTHROCYTES; GLUCOSE; HEMOGLOBINS; HEMOLYSIS; HUMANS; LACTIC ACID; MICROBIAL VIABILITY; NITROGEN MUSTARD COMPOUNDS;

EID: 84904501752     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12545     Document Type: Article

References (62)

1. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19: 110-126.
2. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 2002; 83: 313-323.
3. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-1468.
4. Solheim BG, Seghatchian J,. The six questions of pathogen reduction technology: an overview of current opinions. Transfus Apher Sci 2008; 39: 51-57.
5. Wu Y, Snyder E,. Safety of the blood supply: role of pathogen reduction. Blood Rev 2003; 17: 111-122.
6. Goodrich RP, Doane S, Reddy HL,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
7. Seghatchian J, de Sousa G,. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189-196.
8. Henschler R, Seifried E, Mufti N,. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38: 33-42.
9. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013; 53: 373-381.
10. Bashir S, Cookson P, Wiltshire M, et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013; 53: 990-1000.
11. Seghatchian J, Tolksdorf F,. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system-an update. Transfus Apher Sci 2012; 46: 221-229.
12. Goodrich RP, Edrich RA, Li J, et al. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
13. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-1692.
14. Johnson L, Winter KM, Reid S, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: 208-214.
15. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-1177.
16. Liu W, Cimino GD, Corash L, et al. The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation. Transfusion 2010; 51: 52-61.
17. Infanti L, Stebler C, Job S, et al. Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: a cohort study. Transfus Apher Sci 2011; 45: 175-181.
18. TM). Vox Sang 2011; 100: 247-249.
19. Benjamin RJ,. Red blood cell pathogen reduction: in search of serological agnosticism. ISBT Sci Ser 2006; 1: 222-226.
20. Solheim BG,. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
21. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood and red blood cells with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-19.
22. North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011; 51: 2208-2218.
23. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46: 1778-1786.
24. Clark B, Castro G, Stassinopoulos A,. Treatment with Helinx(r) technology does not affect the ability of red blood cells to overcome oxidative stress American Association of Blood Banks 56th Annual Meeting, San Diego, CA. Transfusion 2003; 53: 9A.
25. Snyder EL, Dodd RY,. Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Program 2001: 433-442.
26. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-1749.
27. Erickson A, Leibacher J, Schott MA, et al. Verification of in vitro quality of pathogen inactivated RBC using the S-303 treatment system [abstract]. Vox Sang 2011; 101: 77.
28. Erickson A, Schott MA, Sherman C, et al. In vitro evaluation of pathogen inactivated RBC using the S-303 treatment system [abstract]. Vox Sang 2011; 101: 78.
29. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011; 51: 2367-2376.
30. Australian and New Zealand Society of Blood Transfusion Ltd and Royal College of Nursing Australia. Guidelines for the administration of blood products. 2nd ed. 2011. [cited 2013 May]. Available from: http://www.anzsbt.org. au/publications/documents/ANZSBT-Guidelines-Administration-Blood-Products-2ndEd- Dec-2011-Plain-Tables.pdf
31. Hamill TR,. The 30-minute rule for reissuing blood: are we needlessly discarding units? Transfusion 1990; 30: 58-62.
32. Beutler E,. Red cell metabolism: a manual of biochemical methods. 3rd ed. New York: Grune & Stratton; 1984.
33. Veale MF, Healey G, Sparrow RL,. Effect of additive solutions on red blood cell membrane properties of stored RBCs prepared from whole blood held for 24 hours at room temperature. Transfusion 2011; 51: 25S-33S.
34. Johnson L, Winter K, Kwok M, et al. Evaluation of the quality of blood components prepared using the Reveos automated blood processing system. Vox Sang 2013; 105: 225-235.
35. Johnson L, Winter KM, Hartkopf-Theis T, et al. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution. Transfusion 2012; 52: 503-509.
36. Amer J, Goldfarb A, Fibach E,. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 2004; 60A: 73-80.
37. Maulik G, Kassis AI, Savvides P, et al. Fluoresceinated phosphoethanolamine for flow-cytometric measurement of lipid peroxidation. Free Radic Biol Med 1998; 25: 645-653.
38. European Directorate for the Quality of Medicines & HealthCare. Guide to the preparation, use and quality assurance of blood components. 14th ed. Strasbourg: Council of Europe Press; 2008.
39. Dumaswala UJ, Wilson MJ, Wu YL, et al. Glutathione loading prevents free radical injury in red blood cells after storage. Free Radic Res 2000; 33: 517-529.
40. Kanias T, Acker JP,. Trehalose loading into red blood cells is accompanied with hemoglobin oxidation and membrane lipid peroxidation. Cryobiology 2009; 58: 232-239.
41. Hess J, Rugg N, Jonies A, et al. Buffering and dilution in red blood cell storage. Transfusion 2006; 46: 50-54.
42. Högman CF, Knutson F, Lööf H,. Storage of whole blood before separation: the effect of temperature on red cell 2,3 DPG and the accumulation of lactate. Transfusion 1999; 39: 492-497.
43. Hess JR, Rugg N, Knapp AD, et al. The role of electrolytes and pH in RBC ASs. Transfusion 2001; 41: 1045-1051.
44. Kanias T, Wong K, Acker JP,. Determination of lipid peroxidation in desiccated red blood cells. Cell Preserv Technol 2007; 5: 165-174.
45. Maulik G, Salfia R, Makrigiorgos GM,. Flow cytometric determination of lipid peroxidation using fluoresceinated phosphoethanolamine. Methods Enzymol 2002; 352: 80-91.
46. Hess JR,. Scientific problems in the regulation of red blood cell products. Transfusion 2012; 52: 1827-1835.
47. Hancock V, Cardigan R, Thomas S,. Red cell concentrate storage and transport temperature. Transfus Med 2011; 21: 325-329.
48. de Korte D, Kleine M, Korsten H, et al. Prolonged maintenance of 2,3-diphosphoglycerate acid and adenosine triphosphate in red blood cells during storage. Transfusion 2008; 48: 1081-1089.
49. Tinmouth A, Fergusson D, Yee IC, et al. Clinical consequences of red cell storage in the critically ill. Transfusion 2006; 46: 2014-2027.
50. van der Meer PF, Cancelas JA, Cardigan R, et al. Evaluation of overnight hold of whole blood at room temperature before component processing: effect of red blood cell (RBC) additive solutions on in vitro RBC measures. Transfusion 2011; 51: 15S-24S.
51. Thomas S, Bekoe Y, Uddin S, et al. Double red cell concentrates-in vitro quality after delayed refrigeration. Transfus Med 2010; 20: 315-321.
52. Bontekoe IJ, van der Meer PF, de Korte D,. Effect of rate and delay of cooling during initial cooling process: in vitro effect on red cells. Vox Sang 2011; 101: 16-20.
53. Joseph J, Pink J, Ribeiro A, et al. In vitro characteristics of "undercollected" units of whole blood in CP2D-A. Vox Sang 1994; 67: 275-279.
54. Erickson A, Donnelly B, Schott M, et al. In vitro evaluation of pathogen inactivated RBC using the S-303 treatment system. Transfusion 2012; 52: 77A.
55. Holme S,. Current issues related to the quality of stored RBCs. Transfus Apher Sci 2005; 33: 55-61.
56. Hess J, Greenwalt T,. Storage of red blood cells: new approaches. Transfus Med Rev 2002; 16: 283-295.
57. Zimmermann R, Wintzheimer S, Weisbach V, et al. Influence of prestorage leukoreduction and subsequent irradiation on in vitro red blood cell storage variables of red blood cells in additive solution saline-adenine-glucose- mannitol. Transfusion 2009; 49: 75-80.
58. Bashir S, Naik F, Cardigan R, et al. Effect of X-irradiation on the quality of red cell concentrates. Vox Sang 2011; 101: 200-207.
59. Weiskopf RB, Schnapp S, Rouine-Rapp K, et al. Extracellular potassium concentrations in red blood cell suspensions after irradiation and washing. Transfusion 2005; 45: 1295-1301.
60. Australian and New Zealand Society of Blood Transfusion Ltd. Guidelines for prevention of transfusion-associated graft-versus-host disease. 2011. [cited 2013 May]. Available from: http://www.anzsbt.org.au/publications/ PreventionofTA-GVHD.pdf.pdf
61. Smith HM, Farrow SJ, Ackerman JD, et al. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg 2008; 106: 1062-1069.
62. Strauss RG,. Red blood cell storage and avoiding hyperkalemia from transfusions to neonates and infants. Transfusion 2010; 50: 1862-1865.